Bayer’s investigational Factor XIa inhibitor asundexian advances with FDA and Japan regulatory submissions, supported by Phase III OCEANIC-STROKE trial results showing a 26% reduction in recurrent ischemic stroke risk without added major bleeding.
Written By: Mahathi Palivela, PharmD
Reviewed By: Pharmacally Editorial Team
Bayer advanced its late-stage cardiovascular pipeline after the U.S. Food and Drug Administration and Japan’s Ministry of Health, Labour and Welfare accepted regulatory submissions for asundexian, an investigational oral Factor XIa (FXIa) inhibitor for prevention of recurrent ischemic stroke following non-cardioembolic ischemic stroke or high-risk transient ischemic attack (TIA). The FDA also granted Priority Review designation, accelerating review of the application in the United States.
The filings are supported by positive results from the Phase III OCEANIC-STROKE trial (NCT05686070), which showed that asundexian 50 mg significantly reduced ischemic stroke risk by 26% compared with placebo when added to standard antiplatelet therapy.
The therapy did not increase International Society on Thrombosis and Hemostasis (ISTH) major bleeding, a critical safety concern in stroke prevention strategies.
Stroke remains a major global health burden, with nearly 12 million people experiencing a stroke annually. Despite currently available therapies, approximately one in ten stroke survivors experiences another stroke within one year, underscoring the need for safer and more effective secondary prevention options.
Asundexian targets Factor XIa, a component of the coagulation cascade believed to drive pathological clot formation while playing a limited role in normal hemostasis. This selective mechanism has generated growing interest across the anticoagulation field because it may reduce thrombotic events while minimizing bleeding complications commonly associated with traditional anticoagulants.
The OCEANIC-STROKE study enrolled 12,327 participants worldwide in a multicenter, randomized, double-blind, placebo-controlled Phase III trial. Investigators evaluated once-daily asundexian 50 mg versus placebo in patients who recently experienced a non-cardioembolic ischemic stroke or high-risk TIA. The primary efficacy endpoint measured time to ischemic stroke, while the primary safety endpoint assessed ISTH major bleeding.
Full findings from the study were recently published in the The New England Journal of Medicine, reinforcing the clinical significance of the results. The combination of efficacy and preserved bleeding safety profile positions FXIa inhibition as a potentially important new strategy in stroke prevention.
Christian Rommel, Head of Research and Development for Bayer’s Pharmaceuticals Division, said the regulatory acceptances mark another milestone for the company’s stroke portfolio and reflect the substantial unmet need among patients living with the long-term consequences of stroke worldwide.
Beyond the U.S. and Japan, Bayer continues global regulatory submissions for asundexian. China’s Center for Drug Evaluation has also accepted the company’s marketing application and granted Priority Review designation. If approved, asundexian could become one of the first FXIa inhibitors to enter the market and potentially reshape anticoagulation strategies in cerebrovascular disease.
Reference
About the Writer
Mahathi Palivela (LinkedIn) is pursuing PharmD and has a strong interest in Clinical Pharmacy and Patient safety. She is passionate about handling and analyzing patient data, and translating clinical insights into clear, meaningful summaries. She aims to apply this interest in Medical Writing and Pharmacovigilance, focusing on improving patient outcomes through careful data interpretation and communication.